Medical Device | January 10, 2022
Mylab’s CoviSelf can detect Omicron: Study
Recent Study by Columbia University finds Mylab’s CoviSelf can detect the Omicron variant successfully
Recent Study by Columbia University finds Mylab’s CoviSelf can detect the Omicron variant successfully
Earlier last week the U.S. FDA had also shortened the time to receive a Pfizer booster shot from six months to five months for everyone 12 and older
Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology. Clinical trials are expected to start in the second half of 2022
Acting as both a Dual Protease and TMPRSS2 Inhibitor, Pentarlandir is about to enter FDA Phase III trial¬
The latest research results indicated that JMB2002 had high binding activity to the Omicron variant and showed potent Omicron pseudovirus neutralization function
Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
The first pilot study from India analyzing Covaxin-Covishield mixed doses
A toll-free helpline to be set up to help doctors and patients
Celltrion plans to provide dual treatment options for COVID-19; Regkirona for hospitalised patients and a nebulised cocktail therapy (CT-P63 in combination with Regkirona) for at- home settings
Oravax's oral VLP vaccine in development targets three SARS CoV-2 virus surface proteins, including proteins less susceptible to mutation, thus making the vaccine potentially more effective against current and future variants of the Covid-19 virus
Subscribe To Our Newsletter & Stay Updated
